Patients with T2DM who received GLP-1RAs for the first time between January 1, 2020, and May 31, 2023, were included
BPC 157 entered early-phase clinical development for inflammatory bowel disease as PL 14736 (Pliva, Croatia), and a 2025 pilot examined intravenous administration in a small cohort, but no adequately powered randomised controlled trial exists
The single idea worth carrying forward is that bioavailability, not marketing, defines what an oral GLP-1 can and cannot do
The needles are as fine as those used for insulin
Your physician calibrates your weekly injection protocol based on your activity level, body composition, and health targets
doi: 10.1016/S2352-4642(18)30235-9 184 KleberMdeSousaGPapckeSWabitschMReinehrT